This hypothesis proposes that selective activation of LXRα (NR1H3) represents a superior therapeutic approach for addressing dyslipidemia by targeting hepatic cholesterol homeostasis rather than microglial cholesterol accumulation. LXRα, predominantly expressed in metabolically active tissues including liver, intestine, and kidney, serves as the primary regulator of whole-body cholesterol efflux and lipid metabolism. Selective LXRα agonism would enhance hepatic APOE production and secretion, increasing the pool of circulating lipid-poor APOE particles available for peripheral cholesterol mobilization. This mechanism would promote reverse cholesterol transport from peripheral tissues to the liver for excretion, while simultaneously upregulating hepatic ABCA1 and ABCG1 expression to facilitate cholesterol efflux from hepatocytes. Unlike LXRβ-mediated microglial targeting, LXRα activation would address systemic dyslipidemia at its primary metabolic hub. The hepatic focus allows for enhanced LDLR expression and HMG-CoA reductase suppression, creating a coordinated response that increases cholesterol clearance while reducing endogenous synthesis.

This hypothesis proposes that selective activation of LXRα (NR1H3) represents a superior therapeutic approach for addressing dyslipidemia by targeting hepatic cholesterol homeostasis rather than microglial cholesterol accumulation. LXRα, predominantly expressed in metabolically active tissues including liver, intestine, and kidney, serves as the primary regulator of whole-body cholesterol efflux and lipid metabolism. Selective LXRα agonism would enhance hepatic APOE production and secretion, increasing the pool of circulating lipid-poor APOE particles available for peripheral cholesterol mobilization. This mechanism would promote reverse cholesterol transport from peripheral tissues to the liver for excretion, while simultaneously upregulating hepatic ABCA1 and ABCG1 expression to facilitate cholesterol efflux from hepatocytes. Unlike LXRβ-mediated microglial targeting, LXRα activation would address systemic dyslipidemia at its primary metabolic hub. The hepatic focus allows for enhanced LDLR expression and HMG-CoA reductase suppression, creating a coordinated response that increases cholesterol clearance while reducing endogenous synthesis. This approach leverages the liver's central role in lipoprotein metabolism to generate properly lipidated APOE particles that can efficiently accept cholesterol from peripheral tissues. Selective LXRα agonism would avoid potential CNS-related side effects while maximizing therapeutic impact on plasma cholesterol levels, triglyceride clearance, and overall lipid profile normalization. The intervention targets the root cause of dyslipidemia through hepatic metabolic reprogramming rather than addressing downstream consequences in specific cell types.